API Portfolio: Updated Q1 2017

LGM Pharma is enhancing its position as an active and leading supplier of newly approved APIs, coupled with possibilities for full technical assistance & complete regulatory support.Close collaboration with many world-class cGMP compliant and EU & US-FDA inspected and approved manufacturers gives us several key advantages in the area of knowledge, expertise, market trends, quality and documentation.

Alectinib

Brexpiprazole

Brivaracetam

Cangrelor

Cobimetinib

Crisaborole Daclatasvir

Daratumumab

Defibrotide Sodium

Edoxaban

Elbasvir

Evolocumab

Grazoprevir

Isavuconazole

Ivabradine

Lesinurad

LifitegrastLixisenatide

Lumacaftor

Nusinersen

Obeticholic Acid

Palbociclib

Panobinostat

Pembrolizumab

Pimavanserin

Rolapitant

Rucaparib

SacubitrilSugammadex

Tenofovir alafenamide

Velpatasvir

Venetoclax